Our portfolio companies have the potential for transformational change in the way a disease area is treated and significantly improves the patient quality of life.

vTv THERAPEUTICS

Year Invested/Status: 2022/Active

Motivation: Hypoglycemia is a serious medical condition commonly occurring in patients with Type 1 Diabetes (T1D). The risk of severe hypoglycemia [1] increases markedly with the increasing duration of the disease and is a major burden for patients and their families.

Lead Program(s): TTP399 is a novel, oral, small molecule, liver selective glucokinase activator being developed under breakthrough therapy status granted by the FDA as an adjunct therapy to insulin in patients with T1D. TTP399 recently completed a phase 2 study in patients with T1D demonstrating 40% reduction in hypoglycemic events compared to placebo and allowed for tighter long term glycemic control.

Pre-Clinical

Phase 1

Phase 2

Phase 3

TTP399
Type 1 Diabetes

Sources:
[1] Frier BM. The incidence and impact of hypoglycemia in type 1 and type 2 diabetes. International Diabetes Monitor 2009;21:210–218

CinCOR Pharma

Year Invested/Status: 2019/Passive

Motivation: Despite a multitude of approved therapeutics, patients and physicians still struggle to control hypertension – a common but highly dangerous and life-threatening disease.

Lead Program(s): CinCor baxdrostat (CIN-107) is a highly selective, oral small molecule inhibitor of aldosterone synthase currently in phase 2 of clinical development for the treatment of hypertension and other cardio-renal diseases. Baxdrostat has the potential to bring blood pressure into goal range which results in a decreased risk of negative cardiovascular outcomes.

Experience CinCor’s Journey on the CinRx Superhighway.

CinDome Pharma

Year Invested/Status: 2016/Active
Motivation: 1 in 4 adult patients in the US experience symptoms of gastroparesis – pain, bloating, nausea and vomiting – with the incidence growing rapidly due to the increasing diabetic population [1,2]. A safe and effective treatment that can be taken on a chronic basis remains a significant unmet need.

Lead Program(s): CIN-102 (deudomperidone) is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects being developed to treat patients with gastrointestinal disorders currently in phase 2 of clinical development. CIN-102 has secured composition of matter patents as well as completed a proof-of-concept study showing signals of improvement in nausea and vomiting and promising effect on gastric emptying in patients with gastroparesis.

Pre-Clinical

Phase 1

Phase 2

Phase 3

CIN-102
Gastroparesis

Sources:
[1] Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Digestive Diseases and Sciences. 1993;38(9):1569–1580.
[2] Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clinical Gastroenterology and Hepatology. 2005;3(6):543–552.

CinPhloro Pharma

Year Invested/Status: 2016/Active

Motivation: Irritable bowel syndrome (IBS) is one of the most common reasons for a referral to a gastroenterologist at 40%[1]. All currently approved therapies for this chronic and debilitating condition provide sub-optimal treatment for patients and providers presenting a significant unmet medical need.

Lead Program(s): CIN-103 is a modified, pulsatile-release formulation of phloroglucinol designed for sustained symptomatic relief of patients suffering from IBS-D progressing into Phase 2. CIN-103 has secured strong intellectual property for it’s unique formulation and delivery properties.

Pre-Clinical

Phase 1

Phase 2

Phase 3

CIN-103
IBS – D

Sources:
[1] Zaman A. Irritable bowel syndrome. Clin Cornerstone. 2002;4(4):22-33. doi: 10.1016/s1098-3597(02)90003-7. PMID: 12739324.

Cinfina Pharma

Year Invested/Status: 2021/Active
Motivation: Obesity is an alarming global public health priority with well-established links to serious diseases including type 2 diabetes, coronary heart disease, stroke, cancer, and chronic obstructive pulmonary disease. While the use of GLP-1s to treat obesity has had dramatic uptake, there is still a tremendous need for more effective therapies with greater weight loss potential.

Lead Program(s): CinFina is developing a series of mono and combination biologic therapies, CIN-109, CIN-110, CIN-209 and CIN-210, currently ranging from pre-clinical to Phase 1. The CinFina portfolio includes long-acting GLP-1’s that have the potential to transform the treatment of obesity and related cardio-metabolic diseases. 

Pre-Clinical

Phase 1

Phase 2

Phase 3

CIN-109
Metabolic Diseases
CIN-110
Metabolic Diseases
CIN-209
Metabolic Diseases
CIN-210
Metabolic Diseases

CinSano Pharma

Year Invested/Status: 2021/Active
Motivation: Cancer is the #1 cause of death worldwide [1], with solid tumors representing approximately 90% of adult human cancers, and the need for novel therapeutics targeting oncogenes are in demand now more than ever.
Lead Program(s): CIN-108 is a pre-clinical, small molecule that inhibits defective in cullin neddylation 1 (DCN1) from binding in the pocket where it is necessary to promote neddylation. CIN-108 has the potential to significantly interfere with the  progression of cancers, including multiple solid tumors.

Pre-Clinical

Phase 1

Phase 2

Phase 3

CIN-108
Oncology

Sources:
[1] Cancer (who.int)

Retromer Therapeutics

Year Invested/Status: 2020/Active
Motivation: Despite multiple attempts to curtail progression of neurodegenerative diseases, few safe & efficacious therapeutics have come to market, underscoring the importance of accelerating novel approaches to a disease modifying therapeutic.

Lead Program(s): Retromer Therapeutics is pioneering a new class of therapeutics to treat neurodegenerative diseases by restoring the function of the endolysosmal trafficking system with preclinical programs in neurodegenerative diseases.

Pre-Clinical

Phase 1

Phase 2

Phase 3

Investment
Approach

CinRx Pharma’s experience-based approach for deliberate asset selection is predicated on our depth of clinical and medical expertise gained through decades of treating patients and developing drugs.

 

CinRx is not a pure financial investor. In addition to providing capital, we believe our true value-add is meaningful participation in the clinical development strategy and operations. We typically invest in companies with solid scientific founders that are looking for participation in the clinical development of an asset.

 

Therapeutic area priorities include cardiovascular, metabolic, oncology, and inflammatory / auto-immune diseases.

Select criteria of CinRx’s disciplined asset selection approach:
  1. Addresses a widely accepted, significant unmet medical need that is a priority for regulators
  2. Potential to cause a transformational reduction in disease burden in terms of:
    • Incidence / prevalence
    • Outcomes and prognosis
    • Quality of life for patients
  3. Exceptional commercial / ROI potential
  4. Something not immediately apparent, a meaningful differentiator, a hidden gem.
Have an opportunity that follows this roadmap?

GENERAL INQUIRIES

INVESTOR INQUIRIES

CAREER INQUIRIES